CS
ASND icon

Candriam SCA’s Ascendis Pharma A/S ASND Stock Holding History

Candriam SCA’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-230,278
Closed -$52.7M – 683
2026
Q1 		$52.7M Buy
230,278
+43,338
+23% +$9.72M 0.27% 82
2025
Q4 		$39.9M Buy
186,940
+7,984
+4% +$1.65M 0.2% 119
2025
Q3 		$35.6M Sell
178,956
-16,159
-8% -$3.01M 0.19% 119
2025
Q2 		$33.7M Sell
195,115
-47,646
-20% -$7.76M 0.19% 107
2025
Q1 		$37.8M Sell
242,761
-37,393
-13% -$5.34M 0.24% 95
2024
Q4 		$38.6M Sell
280,154
-2,177
-0.8% -$286K 0.22% 92
2024
Q3 		$42.2M Buy
282,331
+86,984
+45% +$11.7M 0.24% 87
2024
Q2 		$26.6M Buy
195,347
+95,972
+97% +$13.1M 0.16% 130
2024
Q1 		$15M Hold
99,375
– – 0.1% 204
2023
Q4 		$12.5M Sell
99,375
-40,000
-29% -$3.99M 0.09% 225
2023
Q3 		$13.1M Sell
139,375
-9,000
-6% -$842K 0.09% 197
2023
Q2 		$13.2M Sell
148,375
-102,000
-41% -$8.88M 0.1% 212
2023
Q1 		$24.7M Buy
250,375
+60,000
+32% +$6.86M 0.17% 139
2022
Q4 		$23.2M Sell
190,375
-16,000
-8% -$1.86M 0.16% 152
2022
Q3 		$21.3M Sell
206,375
-14,376
-7% -$1.36M 0.15% 155
2022
Q2 		$20.5M Buy
220,751
+56,433
+34% +$5.32M 0.17% 137
2022
Q1 		$19.3M Sell
164,318
-74,104
-31% -$8.58M 0.13% 169
2021
Q4 		$32.1M Sell
238,422
-11,977
-5% -$1.78M 0.2% 126
2021
Q3 		$39.9M Sell
250,399
-32,581
-12% -$4.46M 0.27% 88
2021
Q2 		$37.2M Buy
282,980
+42,309
+18% +$5.64M 0.25% 93
2021
Q1 		$38.6M Hold
240,671
– – 0.32% 77
2020
Q4 		$40.1M Sell
240,671
-28,408
-11% -$4.7M 0.32% 77
2020
Q3 		$41.5M Buy
269,079
+79,000
+42% +$11.4M 0.39% 53
2020
Q2 		$28.1M Buy
190,079
+78,079
+70% +$10.7M 0.3% 85
2020
Q1 		$15.2M Hold
112,000
– – 0.17% 145
2019
Q4 		$15.6M Buy
112,000
+18,000
+19% +$2M 0.17% 145
2019
Q3 		$9.05M Buy
+94,000
New +$10.5M 0.12% 202

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Candriam SCA's ASND Position: Q2 2026 in Review

Candriam SCA sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 230,278 shares — an estimated $52.7M sold.

Candriam SCA first reported a position in ASND in Q3 2019 and held it in 27 quarters. The position peaked at $52.7M in Q1 2026. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Candriam SCA reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
  • Candriam SCA sold 230,278 Ascendis Pharma A/S shares in Q2 2026, an estimated $52.7M.
  • Candriam SCA first reported a position in Ascendis Pharma A/S in Q3 2019 and held it in 27 quarters.
  • Candriam SCA's Ascendis Pharma A/S position peaked at $52.7M in Q1 2026.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.